WHAT IS CLAIMED IS:

1. A compound of Formula I:



wherein

R^a is independently selected from a) hydrogen, and b) unsubstituted or substituted C_1-C_6 alkyl;

R^1 is a) hydrogen, b) unsubstituted or substituted C_1-C_6 alkyl, and c) OR^7;

R^2 is a) hydrogen, b) unsubstituted or substituted C_1-C_6 alkyl, c) $(CR^a_2)_nR^7$, d) $O(CR^a_2)_nOR^7$, e) $O(CR^a_2)_nR^7$, or f) halo;

R^3 is a) hydrogen, b) unsubstituted or substituted C_1-C_6 alkyl, or c) OR^7;

R^2 and R^3 can be taken together to form a cyclic moiety, $(CH_2)_u$, said cyclic moiety optionally containing one or two heteroatoms selected from N, O and S;

R^4 is a) hydrogen, b) unsubstituted or substituted C_1-C_6 alkyl, c) OR^7, or d) $C(O)_2R^7$;

R^5 is a) unsubstituted or substituted C_1-C_6 alkyl, b) C_2-C_6 alkenyl-R^7, c) C_2-C_6 alkynyl-R^7, d) unsubstituted or substituted aryl, e) unsubstituted or substituted heterocyclyl, f) $C(O)NR^7(CR^a_2)_nC(O)OR^7$, or g) $C(O)R^7$; said alkyl, alkenyl, alkynyl, aryl or heterocyclyl is optionally substituted with at least one substituent selected from: i) halo, ii) unsubstituted or substituted C_1-C_6 alkyl, iii) OR^7, iv) NR^7_2, v) NO_2, and vi) $S(O)_mR^6$;

R^6 is independently selected from a) unsubstituted or substituted C_1-C_6 alkyl, and b) unsubstituted or substituted aryl;

R^7 is independently selected from a) H, b) unsubstituted or substituted C_1-C_6 alkyl, c) unsubstituted or substituted aryl, d) unsubstituted or substituted heterocyclyl, and e) CF_3; said alkyl, aryl and

heterocyclyl is optionally substituted with at least one substituent selected from i) halo, ii) unsubstituted or substituted C_1-C_6 alkyl, iii) OR^7, iv) NR^7_2, v) NO_2, and vi) $S(O)_mR^6$,

m is 1 or 2;

n is independently 0, 1, 2, 3, or 4;

u is 4, 5, 6, 7 or 8;

or a salt thereof.

2. The compound according to Claim 1, wherein:

R^1 is hydrogen;

R^4 is a) hydrogen, or b) $C(O)_2R^7$;

or a salt thereof.

3. The compound of Claim 1 selected from:
Trans-3-{2-[5-(4-methanesulfonyl-piperazine-1-ylmethyl)-2-nitro-phenyl]-vinyl}-2-methoxy-quinoline;
Methyl-*N*-[(2*E*)-3-(6-nitro-1,3-benzodioxol-5-yl)prop-2-enoyl]glycinate;
(2*E*)-3-(2-nitrophenyl)-1-phenylprop-2-en-1-one;
(2*E*)-3-(2-nitrophenyl)acrylaldehyde;
2-Nitro-1-[(1*E*)-prop-1-en-1-yl]-4-(trifluoromethoxy)benzene;
2-Methoxy-5-[(*E*)-2-(5-methoxy-2-nitrophenyl)vinyl]pyridine;
2-Methoxy-3-[(*E*)-2-(5-methyl-2-nitrophenyl)vinyl]pyridine;
2-Chloro-3-[(*E*)-)-2-[5-(2-methoxyethoxy)-2-nitrophenyl]vinyl}quinoline;
2-Methoxy-3-{(*E*)-2-[5-(2-methoxyethoxy)-2-nitrophenyl]vinyl}quinoline;
2-Methoxy-3-[(*E*)-2-[2-nitro-5-(2-piperidin-1-ylethoxy)phenyl]vinyl}quinoline;
2-Chloro-3-[(*E*)-2-(5-methyl-2-nitrophenyl)vinyl]quinoline;
2-Methoxy-3-[(*E*)-2-(5-methyl-2-nitrophenyl)vinyl]quinoline;
3-[(*E*)-2-(5-{[4-(methylsulfonyl)piperazin-1-yl]methyl}-2-nitrophenyl)vinyl]quinolin-2-(1*H*)-one;
2-[(*E*)-2-(5-chloro-2-nitrophenyl)vinyl]-1-(phenylsulfonyl)-1*H*-indole;
Methyl (2*Z*)-2-[2-nitro-4-(trifluoromethoxy)phenyl]-3-phenylacrylate;

1,1'-(1*E*,3*E*)-buta-1,3-diene-1,4-diylbis(2-nitrobenzene);

or a salt thereof.

4. A compound of Formula II:



II

wherein

R is H or OH;

R^a is independently selected from a) hydrogen, and b) unsubstituted or substituted C_1-C_6 alkyl;

R^1 is a) hydrogen, b) unsubstituted or substituted C_1-C_6 alkyl, and c) OR^7;

R^2 is a) hydrogen, b) unsubstituted or substituted C_1-C_6 alkyl, c) $(CR^a_2)_nR^7$, d) $O(CR^a_2)_nOR^7$, e) $O(CR^a_2)_nR^7$, or f) halo;

R^3 is a) hydrogen, b) unsubstituted or substituted C_1-C_6 alkyl, or c) OR^7;

R^2 and R^3 can be taken together to form a cyclic moiety, $(CH_2)_u$, said cyclic moiety optionally containing one or two heteroatoms selected from N, O and S;

R^4 is a) hydrogen, b) unsubstituted or substituted C_1-C_6 alkyl, c) OR^7, or d) $C(O)_2R^7$;

R^5 is a) unsubstituted or substituted C_1-C_6 alkyl, b) C_2-C_6 alkenyl-R^7, c) C_2-C_6 alkynyl-R^7, d) unsubstituted or substituted aryl, e) unsubstituted or substituted heterocyclyl, or f) $C(O)NR^7(CR^a_2)_nC(O)OR^7$; said alkyl, alkenyl, alkynyl, aryl or heterocyclyl is optionally substituted with at least one substituent selected from: i) halo, ii) unsubstituted or substituted C_1-C_6 alkyl, iii) OR^7, iv) NR^72, v) NO_2, and vi) $S(O)_mR^6$;

R^6 is independently selected from a) unsubstituted or substituted C_1-C_6 alkyl, and b) unsubstituted or substituted aryl;

R^7 is independently selected from a) H, b) unsubstituted or substituted C_1-C_6 alkyl, c) unsubstituted or substituted aryl, d) unsubstituted or substituted heterocyclyl, and e) CF_3; said alkyl, aryl and heterocyclyl is optionally substituted with at least one substituent selected from i) halo, ii) unsubstituted or substituted C_1-C_6 alkyl, iii) OR^7, iv) NR^7_2, v) NO_2, and vi) $S(O)_mR^6$,

m is 1 or 2;

n is independently 0, 1, 2, 3, or 4;

u is 4, 5, 6, 7 or 8;

or a pharmaceutically acceptable salt thereof.

5. The compound according to Claim 4 wherein:

R^1 is hydrogen;

R^4 is hydrogen or $C(O)_2R^7$;

R^5 is a) unsubstituted or substituted C_1-C_6 alkyl, b) unsubstituted or substituted aryl, c) unsubstituted or substituted heterocyclyl, or d) $C(O)NR^7(CR^a_2)_nC(O)OR^7$;

or a pharmaceutically acceptable salt thereof.

6. The compound according to Claim 5 selected from:

2-Methoxy-3-[5-(piperazin-1-ylmethyl)-*1H*-indol-2-yl]quinoline;

N-(Carbomethoxy)-5,6-methylenedioxy-*1H*-indole-2-carboxamide;

2-(2-methoxyquinolin-3-yl)-6-methyl-5-{[4-(methylsulfonyl)piperazin-1-yl]methyl}-1H-indol-1-ol;

2-Methoxy-6-[5-methoxy-*1H*-indol-2-yl] pyridine;

2-Methoxy-3-[5-methyl-*1H*-indol-2-yl] pyridine;

2-Chloro-3-[5-(methoxyethoxy)-*1H*-indol-2-yl]quinoline;

2-Methoxy-3-[5-(methoxyethoxy)-*1H*-indol-2-yl]quinoline;

2-Methoxy-3-[5-(1-piperdinylethoxy)-*1H*-indol-2-yl]quinoline;
2-Chloro-3-(5-methyl-*1H*-indol-2-yl)quinoline;
2-Methoxy-3-(5-methyl-*1H*-indol-2-yl)quinoline;
3-[5-[4-(Methylsulfonyl)-1-piperazinyl]methyl]-1*H*-indole-2-yl]quinolin-2(1*H*)-one;
1-Benzenesulfonyl-2-(1'benzyl-5-chloroindol-2'-yl) indole;
Methyl 2-phenylindole-3-carboxylate;

or a pharmaceutically acceptable salt thereof.

7. A compound selected from:
2-(2-methoxyquinolin-3-yl)-6-methyl-5-{[4-(methylsulfonyl)piperazin-1-yl]methyl}-1H-indol-1-ol; and
2-Methoxy-3-[5-[[4-(methysulfonyl)-1-piperazinyl]methyl]-1*H*-indol-2-yl]-quinoline

or a pharmaceutically acceptable salt thereof.

8. A process for preparing the compound of the Formula II, according to Claim 4, which comprises a palladium-catalyzed reductive cyclization of an ortho-nitrostyrene of Formula I:



I

wherein

R^a is independently selected from a) hydrogen, and b) unsubstituted or substituted C_1-C_6 alkyl;

R^1 is a) hydrogen, b) unsubstituted or substituted C_1-C_6 alkyl, and c) OR^7;

R^2 is a) hydrogen, b) unsubstituted or substituted C_1-C_6 alkyl, c) $(CR^a_2)_nR^7$, d) $O(CR^a_2)_nOR^7$, e) $O(CR^a_2)_nR^7$, or f) halo;

R^3 is a) hydrogen, b) unsubstituted or substituted C_1-C_6 alkyl, or c) OR^7;

R^2 and R^3 can be taken together to form a cyclic moiety, $(CH_2)_u$, said cyclic moiety optionally containing one or two heteroatoms selected from N, O and S;

R^4 is a) hydrogen, b) unsubstituted or substituted C_1-C_6 alkyl, c) OR^7, or d) $C(O)_2R^7$;

R^5 is a) unsubstituted or substituted C_1-C_6 alkyl, b) C_2-C_6 alkenyl-R^7, c) C_2-C_6 alkynyl-R^7, d) unsubstituted or substituted aryl, e) unsubstituted or substituted heterocyclyl, f) $C(O)NR^7(CR^a{}_2)_nC(O)OR^7$, or g) $C(O)R^7$; said alkyl, alkenyl, alkynyl, aryl or heterocyclyl is optionally substituted with at least one substituent selected from: i) halo, ii) unsubstituted or substituted C_1-C_6 alkyl, iii) OR^7, iv) $NR^7{}_2$, v) NO_2, and vi) $S(O)_mR^6$;

R^6 is independently selected from a) unsubstituted or substituted C_1-C_6 alkyl, and b) unsubstituted or substituted aryl;

R^7 is independently selected from a) H, b) unsubstituted or substituted C_1-C_6 alkyl, c) unsubstituted or substituted aryl, d) unsubstituted or substituted heterocyclyl, and e) CF_3; said alkyl, aryl and heterocyclyl is optionally substituted with at least one substituent selected from i) halo, ii) unsubstituted or substituted C_1-C_6 alkyl, iii) OR^7, iv) $NR^7{}_2$, v) NO_2, and vi) $S(O)_mR^6$,

m is 1 or 2;

n is independently 0, 1, 2, 3, or 4;

u is 4, 5, 6, 7 or 8;

to produce a compound of Formula II.

9. The process of Claim 8, wherein the palladium catalyst is generated *in situ*.

10. The process of Claim 9 wherein the palladium catalyst is comprised of a palladium source, which is selected from palladium (II) acetate, palladium (II) trifluoroacetate and $Pd_2(dba)_3$, and a ligand, which is selected from an aromatic diamine.

11. The process of Claim 10, wherein the aromatic diamine is selected from 1,10-phenanthroline (phen), 3,4,7,8-tetramethyl-1,10-phenanthroline and bipyridine.

12. The process of Claim 11 wherein the palladium is about 0.05 to about 1.5 mol% and the ligand is about 0.2 to about 25 mol%.

13. The process of Claim 8 wherein the palladium catalyst is preformed and is selected from $phen_2Pd(OTf)_2$, $phen_2Pd(PF_6)_2$ and $phen_2Pd(BF_4)_2$.

14. The process of Claim 13 which further comprises an additive, which is selected from $Ag(OTf)_2$ and $Cu(OAc)_2$.

15. The process of Claim 14 which further comprises a solvent selected from dimethylformamide, DMSO, THF, acetonitrile, toluene, dimethylacetamide, N-methyl pyrrolidinone, and ortho-dichlorobenzene.

16. The process of Claim 11 wherein the palladium catalyst is palladium (II) trifluoracetate, the aromatic diamine is 3,4,7,8-tetramethyl-1,10-phenathroline, and a solvent is added.

17. The process of Claim 16 wherein the pressure is about 15 psig CO and the temperature is about 70 °C.

18. A process for preparing 2-(2-methoxyquinolin-3-yl)-6-methyl-5-{[4-(methylsulfonyl)piperazin-1-yl]methyl}-1*H*-indol-1-ol which comprises

a) mixing t*rans*-3-{2-[5-(4-methanesulfonyl-piperazine-1-ylmethyl)-2-nitro-phenyl]-vinyl}-2-methoxy-quinoline with a palladium catalyst and a solvent to produce a reaction mixture;

b) pressurizing the reaction mixture to about 15 psig with CO and maintaining a temperature of about 70 °C; and

c) isolating 2-(2-methoxyquinolin-3-yl)-6-methyl-5-{[4-(methylsulfonyl)piperazin-1-yl]methyl}-1*H*-indol-1-ol.

19. A process for preparing 2-methoxy-3-[5-[[4-(methysulfonyl)-1-piperazinyl]methyl]-1*H*-indol-2-yl]-quinoline which comprises

a) mixing t*rans*-3-{2-[5-(4-methanesulfonyl-piperazine-1-ylmethyl)-2-nitro-phenyl]-vinyl}-2-methoxy-quinoline with a palladium catalyst, a aromatic diamine and a solvent to produce a reaction mixture;

b) pressurizing the reaction mixture to about 15 psig with CO and maintaining a temperature of about 70 °C; and

c) isolating 2-methoxy-3-[5-[[4-(methysulfonyl)-1-piperazinyl]methyl]-1*H*-indol-2-yl]-quinoline.

5